Dyne Therapeutics (DYN) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.06

Estimate

-$0.88

Surprise

-20.2%

Score today

5.3/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Dyne Therapeutics (DYN) reported a wider loss than forecast — adjusted EPS of -$1.06 against the -$0.88 estimate (a 20.2% shortfall).

• Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights — fiscal.ai, 2026-11-05
• Dyne Therapeutics Q3 EPS $(1.06) Misses $(0.92) Estimate — benzinga, 2026-11-05
• Amdocs Posts Downbeat Q4 Earnings, Joins Skyworks Solutions, Tesla And Other Big Stocks Moving Lower In Wednesday’s Pre- — benzinga, 2026-11-04

TrendMatrix currently rates DYN Sell at 5.3/10; no pre/post engine snapshot brackets this report.

2 of the last 4 quarters beat the estimate; this quarter's -20.2% surprise compares with a -13.4% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$17.98

Price target

$30.90

Stop

$16.72

Upside to target

+71.9%

Reward-to-risk

4.8:1

Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$3.24B

P/E (fwd)

-5.2

52-week range

$14.00–$27.30

Off 52-week high

34.2%

RSI (14)

69

Volume vs avg

0.18×

Score today

5.3/10